Monopar Therapeutics
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- 10
- Market Cap
- $8.4M
- Introduction
Monopar Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in developing proprietary therapeutics for cancer patients. It also focuses on building a drug development pipeline through the licensing, and acquisition of therapeutics in late preclinical and clinical development stages. The company was founded by Chandler Drew Robinso...
Sangamo Shares Surge on Shorter Pathway for Fabry Candidate
Sangamo Therapeutics' shares surged 69% after FDA alignment on an Accelerated Approval pathway for its Fabry disease gene therapy, isaralgagene civaparvovec (ST-920), using data from its Phase I/II STAAR trial. The company plans to submit a BLA in the second half of 2025, three years ahead of previous estimates.
Related Clinical Trials:
Monopar Announces Agreement with Alexion, AstraZeneca Rare Disease For Late-Stage
Monopar Therapeutics secures worldwide license from Alexion for ALXN-1840, a Phase 3 Wilson disease drug candidate, involving upfront cash/equity, royalties, and milestones. Monopar will oversee global development and commercialization.
Moderna's $1.1B R&D Cut, Profitability Delay Jolt Investors
Moderna revised its break-even forecast from 2026 to 2028, leading to significant R&D cuts and a downgrade in stock ratings by firms like Jefferies and J.P. Morgan. The company plans to focus on 10 pipeline candidates, halting development of five programs, and expects a compounded annual growth rate of over 25% from 2026 to 2028.
Related Clinical Trials:
© Copyright 2024. All Rights Reserved by MedPath